Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial.
Seree-Aphinan C, Rattanakaemakorn P, Suchonwanit P, Thadanipon K, Ratanapokasatit Y, Yongpisarn T, Malathum K, Simaroj P, Setthaudom C, Lohjai O, Tanrattanakorn S, Chanprapaph K; COVIDVAC-DERM Study Group. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. Vaccines (Basel). 2024 Jan 11;12(1):73. doi: 10.3390/vaccines12010073. Vaccines (Basel). 2024. PMID: 38250886 Free PMC article.
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients.
Seree-Aphinan C, Ratanapokasatit Y, Suchonwanit P, Rattanakaemakorn P, O-Charoen P, Pisitkun P, Suangtamai T, Setthaudom C, Chirasuthat S, Chanprapaph K. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. Front Immunol. 2023 Mar 15;14:1138765. doi: 10.3389/fimmu.2023.1138765. eCollection 2023. Front Immunol. 2023. PMID: 37006291 Free PMC article.
Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study.
Seree-Aphinan C, Suchonwanit P, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Suangtamai T, Chanprapaph K; COVIDVAC-DERM study group. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. J Eur Acad Dermatol Venereol. 2023 May;37(5):e572-e575. doi: 10.1111/jdv.18890. Epub 2023 Jan 31. J Eur Acad Dermatol Venereol. 2023. PMID: 36662625 No abstract available.
A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Thitithanyanont A, Suriyo A, Suangtamai T, Suchonwanit P; COVIDVAC-DERM study group. Chanprapaph K, et al. Among authors: ratanapokasatit y. Br J Dermatol. 2023 Feb 10;188(2):268-277. doi: 10.1093/bjd/ljac045. Br J Dermatol. 2023. PMID: 36637102
11 results